QUEENSBURY, N.Y. ’ Delcath Systems, Inc. (Nasdaq: DCTH), a leading interventional oncology company steadfast in its mission to treat primary and metastatic cancers of the liver, has announced the issuance of an equity award as a material inducement to a new employee under Nasdaq Listing Rule 5635(c)(4). The strategic move was confirmed earlier by Delcath’s Compensation Committee.
The company disclosed that the equity award involves the right to purchase an aggregate of 23,000 shares of Delcath’s common stock. This equity award was specifically designed to attract and retain top-tier talent, a crucial strategy for any company focused on innovative cancer treatment solutions. The new employee, whose employment began in July 2024, is expected to bring significant expertise and contribute to Delcath’s ongoing mission to advance liver cancer treatment.
Delcath’s innovative technologies, including its proprietary CHEMOSAT® Hepatic Delivery System, offer promising therapeutic options in liver-directed oncology treatments. By granting equity awards as employment inducements, Delcath aims to align the interests of its new hires with those of the company and its shareholders.
Such inducement grants are in accordance with Nasdaq Listing Rule 5635(c)(4), which allows companies to grant equity awards to new employees as an incentive for joining the company. This strategy not only bolsters the company’s capability to attract highly qualified professionals but also underscores its commitment to innovation and patient care in interventional oncology.
As Delcath continues to navigate the complexities of liver cancer treatment, these tactical employment inducements highlight its dedication to creating a robust and dynamic workforce, propelling the company toward enhanced clinical outcomes and financial performance.
Comments